{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T10:48:39Z","timestamp":1788518919782,"version":"build-2803163510"},"reference-count":54,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2019,1,28]],"date-time":"2019-01-28T00:00:00Z","timestamp":1548633600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2019,9]]},"abstract":"<jats:p>\n                    Periodic fever syndromes are a group of rare diseases with a highly variable onset, yet limited treatment options are available for children at an early age. Canakinumab has been approved to treat patients with cryopyrin\u2010associated periodic syndrome, a periodic fever syndrome, and systemic juvenile systemic arthritis, with age cutoffs of 4\u00a0years and 2\u00a0years, respectively. In 2016, the US Food and Drug Administration (\n                    <jats:styled-content style=\"fixed-case\">FDA<\/jats:styled-content>\n                    ) approved canakinumab, without an age restriction, for the treatment of three conditions of periodic fever syndromes, including familial Mediterranean fever, hyperimmunoglobulin D syndrome\/mevalonate kinase deficiency, and tumor necrosis factor receptor\u2010associated periodic syndrome. This review discusses the pharmacokinetic (\n                    <jats:styled-content style=\"fixed-case\">PK<\/jats:styled-content>\n                    ), efficacy, safety, and exposure\u2010response relationship of canakinumab and provides the rationale for dosage recommendation in children younger than 2\u00a0years of age with the three conditions of periodic fever syndromes. The approval of canakinumab for these pediatric patients addresses a critical unmet medical need.\n                  <\/jats:p>","DOI":"10.1002\/cpt.1302","type":"journal-article","created":{"date-parts":[[2018,11,17]],"date-time":"2018-11-17T08:15:30Z","timestamp":1542442530000},"page":"557-567","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Dosage Considerations for Canakinumab in Children With Periodic Fever Syndromes"],"prefix":"10.1111","volume":"106","author":[{"given":"Luning","family":"Zhuang","sequence":"first","affiliation":[{"name":"Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianmeng","family":"Chen","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology II Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyu","family":"Yu","sequence":"additional","affiliation":[{"name":"Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshu","family":"Marathe","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology II Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra","family":"Sahajwalla","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology II Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Borigini","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Rheumatology Products Office of Drug Evaluation II, Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Maynard","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Allergy, and Rheumatology Products Office of Drug Evaluation II, Office of New Drugs Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2005-9301","authenticated-orcid":false,"given":"Gilbert J.","family":"Burckart","sequence":"additional","affiliation":[{"name":"Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaning","family":"Wang","sequence":"additional","affiliation":[{"name":"Division of Pharmacometrics Office of Clinical Pharmacology Office of Translational Sciences Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,28]]},"reference":[{"key":"e_1_2_8_1_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-017-0670-8"},{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.2147\/OARRR.S114447"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200672"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9343(02)01429-8"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/570418"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2009.40"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/PEC.0b013e318298df8b"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-005-0071-6"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11882-010-0160-9"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0049-0172(96)80012-6"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e318190cfb7"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1097\/00008480-200006000-00014"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2013.03.016"},{"key":"e_1_2_8_14_1","unstructured":"US Food and Drug Administration (FDA).Arcalyst label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/125249lbl.pdf> (2008). Accessed May 16 2018."},{"key":"e_1_2_8_15_1","unstructured":"US Food and Drug Administration (FDA).Ilaris label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125319s088lbl.pdf> (2016). Accessed May 16 2018."},{"key":"e_1_2_8_16_1","unstructured":"US Food and Drug Administration (FDA).Kineret label. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/103950s5175lbl.pdf> (2016). Accessed May 16 2018."},{"key":"e_1_2_8_17_1","unstructured":"US Food and Drug Administration (FDA).Colcrys label<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2009\/022351lbl.pdf> (2009). Accessed May 16 2018."},{"key":"e_1_2_8_18_1","unstructured":"US Food and Drug Administration (FDA).Ilaris approval letter<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2016\/125319Orig1s085 s086 s087ltr.pdf> (2016). Accessed August 21 2017."},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2004.03.010"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2008.170"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.2165\/11599820-000000000-00000"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.754"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.162"},{"key":"e_1_2_8_24_1","unstructured":"US Food and Drug Administration (FDA).FDA clinical pharmacology review. <https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125319Orig1s085 086 087ClinPharmR.pdf> (2016). Accessed June 14 2018."},{"key":"e_1_2_8_25_1","unstructured":"ClinicalTrials.gov.Efficacy and safety study of ACZ885 in patients with active recurrent or chronic TNF\u2010receptor associated periodic syndrome (TRAPS) (NCT01242813). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01242813> (2010\u20132016)."},{"key":"e_1_2_8_26_1","unstructured":"ClinicalTrials.gov.Study of efficacy and safety of canakinumab in patients with hereditary periodic fevers (NCT02059291). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02059291> (2014\u20132017)."},{"key":"e_1_2_8_27_1","unstructured":"ClinicalTrials.gov.Efficacy safety and tolerability of ACZ885 in patients with Muckle\u2010Wells Syndrome (REMITTER) (NCT00465985). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00465985> (2007\u20132008)."},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810787"},{"key":"e_1_2_8_29_1","unstructured":"ClinicalTrials.gov.Efficacy and safety of ACZ885 in patients with the following cryopyrin\u2010associated periodic syndromes: familial cold autoinflammatory syndrome Muckle\u2010Wells Syndrome or neonatal onset multisystem inflammatory disease (NCT00685373). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00685373> (2008\u20132016)."},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.152728"},{"key":"e_1_2_8_31_1","unstructured":"ClinicalTrials.gov.Efficacy safety and tolerability of ACZ885 in pediatric patients with the following cryopyrin\u2010associated periodic syndromes: familial cold autoinflammatory syndrome Muckle\u2010Wells syndrome or neonatal onset multisystem inflammatory disease (NCT01302860). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01302860> (2011\u20102017)."},{"key":"e_1_2_8_32_1","unstructured":"Brogan P.et al.Efficacy and safety of canakinumab in patients with CAPS aged <24 months: results from an open\u2010label multicenter phase III trial. The American College of Rheumatology\/The Association of Rheumatology Health Professionals Annual Meeting San Francisco CA 2015. Abstract."},{"key":"e_1_2_8_33_1","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1136\/annrheumdis-2016-eular.3881","article-title":"FRI0488 A Phase Iii pivotal umbrella trial of canakinumab in patients with autoinflammatory periodic fever syndromes (colchicine resistant FMF, HIDS\/MKD and TRAPS)","volume":"75","author":"Benedetti F.","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"e_1_2_8_34_1","unstructured":"US Food and Drug Administration (FDA).FDA cross\u2010discipline team leader review<https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125319Orig1s085 086 087CrossR.pdf> (2016). Accessed June 14 2018."},{"key":"e_1_2_8_35_1","unstructured":"ClinicalTrials.gov.Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA) (\u03b2\u2010SPECIFIC 2) (NCT00889863). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00889863> (2009\u20132012)."},{"key":"e_1_2_8_36_1","unstructured":"ClinicalTrials.gov.Single\u2010dose Study to Assess Efficacy of Canakinumab (ACZ885) in Patients With Active Juvenile Idiopathic Arthritis (SJIA) (\u03b2\u2010SPECIFIC 1) (NCT00886769). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00886769> (2009\u20132011)."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205099"},{"key":"e_1_2_8_38_1","unstructured":"US Food and Drug Administration (FDA).General clinical pharmacology considerations for pediatric studies for drugs and biological products<https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm425885.pdf> (2014). Accessed September 16 2018."},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/ni1033"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/sji.12413"},{"key":"e_1_2_8_41_1","unstructured":"ClinicalTrials.gov.Efficacy and safety study of canakinumab administered for 6 months (24 weeks) in Japanese patients with cryopyrin\u2010associated periodic syndromes followed by an extension phase (NCT00991146). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00991146> (2009\u20132017)."},{"key":"e_1_2_8_42_1","unstructured":"ClinicalTrials.gov.Safety efficacy pharmacokinetics pharmacodynamics of ACZ885 in patients with NALP3 mutations and clinical symptoms (NCT00487708). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00487708> (2007\u20132009)."},{"key":"e_1_2_8_43_1","unstructured":"ClinicalTrials.gov.Safety efficacy and pharmacokinetics of subcutaneous ACZ885 in patients with systemic juvenile idiopathic arthritis (SJIA) (NCT00426218). <https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00426218> (2007\u20132011)."},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-016-0436-x"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13160"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12224"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.06446-11"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-014-0208-4"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-014-9657-9"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13119"},{"key":"e_1_2_8_51_1","unstructured":"US Food and Drug Administration (FDA).General clinical pharmacology considerations for pediatric studies for drugs and biological products. <https:\/\/www.fda.gov\/downloads\/drugs\/guidances\/ucm425885.pdf> (2014). Accessed August 21 2017."},{"key":"e_1_2_8_52_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3266"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.116.069559"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.744"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpt.1302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1302","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpt.1302","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.1302","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:58:12Z","timestamp":1775271492000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.1302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,28]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["10.1002\/cpt.1302"],"URL":"https:\/\/doi.org\/10.1002\/cpt.1302","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,28]]},"assertion":[{"value":"2018-03-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-11-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-01-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}